Gamida for Life Buys Elitech's Microarray Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Gamida For Life Group has acquired electronic microarray technologies from the Elitech Group, a private group of in vitro diagnostics and reagent companies, for an undisclosed sum, Elitech said today.

Paris-based Elitech said that the intellectual property and tangible assets Gamida bought was from Epoch Bioscience, part of Elitech's Wescor division, and were originally acquired from Nanogen in July, 2009, for $25.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Craig Venter's Human Longevity is deeply phenotyping individuals and capturing their genetic profiles to explore aging.

The San Francisco Business Times examines Verily's latest hires.

In Nature this week: comprehensive analysis of somatic mutations in breast cancer, and more.

A number of studies indicate that genes might influence political beliefs, Scientific American Mind reports.